Navigation Links
Vion Pharmaceuticals to Appeal Nasdaq Delisting
Date:5/8/2008

Company to Request Hearing with Listing Qualifications Panel

NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had received a letter, dated May 7, 2008, from The Nasdaq Stock Market Inc. (Nasdaq) stating that the Company's common stock will be delisted from the Nasdaq Capital Market as of the opening of business on May 16, 2008 because the Company does not comply with Marketplace Rule 4310(c)(3) which requires the Company to have a minimum of $2,500,000 in stockholders' equity, or $35,000,000 market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. The Company has the right to appeal the Nasdaq Staff determination to a Nasdaq Listings Qualifications Panel. If the Company requests a hearing no later than May 14, 2008, the request for a hearing will automatically stay the delisting of the Company's common stock until the Panel reaches a decision.

The Company intends to request a hearing before May 14, 2008. There can be no assurance that the Panel will grant the Company's request for continued listing.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Treatment site www.sleeping-with-a-sleeping-disorder.com is asking people ... natural sleep aids from around the world to ... cause. The submissions will be compiled in an ... YOU, to be sold from the website in ... of the proceeds ,from sales of the E-book ...
(Date:12/5/2009)... 5 ,, What: Cuts for a ... in the fight against cancer and other terminal illnesses affecting ... donated to St. Jude Children,s Research Hospital. Guests will enjoy ... delectable and savory Vietnamese restaurant in Falls Church for all ...
(Date:12/5/2009)... being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- ... without ever tying the knot, since research has shown that ... um, isn,t there something wrong with those who go it ... looking at psychological measures shows that never-married people aged 40 ...
(Date:12/4/2009)... Calif., Dec. 4 Varian Medical Systems (NYSE: ... set the regular 2010 Annual Meeting of Stockholders for February ... The meeting will be held at the Crowne Plaza Cabana ... p.m. PT. ,, The meeting will be webcast by Thomson ...
(Date:12/4/2009)... Homes and Services for the Aging (AAHSA) applauds the Senate ... (CLASS) provisions remain in the final health reform legislation . ... people with disabilities and their caregivers. ,, We urge ... will make it affordable to care for families and caregivers. ...
Breaking Medicine News(10 mins):Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2
... Inc. (IPM) today announced it is one of ... by The Wall Street Journal and Winning Workplaces. ... ( www.wsj.com/smallbusiness ). IPM provides project management and ... including the life sciences, food and beverage, healthcare, ...
... the combination of low plasma levels of antioxidants and blue ... of the eye disease age-related macular degeneration (AMD), according to ... Ophthalmology , one of the JAMA/Archives journals. , ... the authors write as background information in the article. "While ...
... first-ever report,by the United Nations Secretary-General, Ban Ki-Moon, on ... the Campaign to End,Fistula announced a fourfold increase in ... report, the campaign now works to prevent and treat,fistula ... Arab States. When it,was launched in 2003, it covered ...
... Awareness Day Encourages Latinos to Get Tested, LOS ... make up almost half of all newly diagnosed HIV/AIDS ... nationally., -- A week of activities aimed at ... with National Latino AIDS Awareness Day,observed on October 15., ...
... a greater effect on women, study found , , MONDAY, Oct. ... more your brain shrinks, a new study has found. ... lot, you,re going to hurt your brain," said Rajesh Miranda, ... Texas A&M Health Science Center College of Medicine. "This is ...
... Integrated Medical,Systems, Inc., a medical technology systems integrator ... that it has received,510(k) clearance from the U.S. ... 1000(TM) "suitcase" intensive care unit (ICU)., "FDA ... accomplishment for the,company as we continue to demonstrate ...
Other Medicine News:Health News: Integrated Project Management Named a "Top Small Workplace" by The Wall Street Journal and Winning Workplaces 2Health News: Integrated Project Management Named a "Top Small Workplace" by The Wall Street Journal and Winning Workplaces 3Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 3Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Excess Drinking Shrinks the Brain 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3
(Date:12/4/2009)... Hospira, Inc. (NYSE: HSP ), a ... announced the launch of its next-generation 50 mL and ... solutions, and now offers a complete size range (50 ... VisIV product. The launch of the 50 mL and ...
(Date:12/4/2009)... ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE ... medical countermeasures against biological and chemical threats, announced ... a study demonstrating the effectiveness of Valortim® in ... White (NZW) rabbit. The data are being ...
(Date:12/4/2009)... Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned ... announced the initial development and successful testing of a ... Axsun believes this proprietary optical engine design raises the ... laser-based designs for swept source OCT light sources. ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5C Section Stress Could Alter Babys Immune Cells 50672 1C Section Stress Could Alter Babys Immune Cells 50672 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 1CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 3If 2 Painkillers Are Banned What Next 3F 50662 1If 2 Painkillers Are Banned What Next 3F 50662 2If 2 Painkillers Are Banned What Next 3F 50662 3If 2 Painkillers Are Banned What Next 3F 50662 4
... May 15 Patients with breast or,colorectal cancer, ... expect,further treatment advances with Avastin(R) (bevacizumab) and Herceptin(R),(trastuzumab) ... the 44th,American Society of Clinical Oncology (ASCO) annual ... 30,000 medical experts will attend the meeting which,is ...
... Cytopia Limited,(ASX: CYT) today announced that the abstract ... Annual Meeting of the American Society,of Clinical Oncology (ASCO) ... (http://www.asco.org ) from 9pm on Thursday 15 May (US ... of CYT997, a novel,cytotoxic and vascular disrupting agent, in ...
Other Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: